Axicabtagene-ciloleucel/lisocabtagene-maraleucel/tisagenlecleucelVarious toxicities

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 1999卷 / 1期
关键词：
D O I：
10.1007/s40278-024-54375-1
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：66 / 66
相关论文
共 50 条
  • [1] Axicabtagene-ciloleucel/tisagenlecleucelVarious toxicities and lack of efficacy: 12 case reports
    Reactions Weekly, 2024, 2035 (1) : 93 - 93
  • [2] Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a RealWorld Setting
    Portuguese, Andrew J.
    Albittar, Aya
    Liang, Emily C.
    Huang, Jennifer J.
    Hirayama, Alexandre V.
    Kimble, Erik L.
    Iovino, Lorenzo
    Poh, Christina
    Gopal, Ajay K.
    Shadman, Mazyar
    Till, Brian G.
    Kiem, Hans-Peter
    Milano, Filippo
    Chapuis, Aude G.
    Otegbeye, Folashade
    Cassaday, Ryan D.
    Maloney, David G.
    Gauthier, Jordan
    BLOOD, 2023, 142
  • [3] Axicabtagene-ciloleucel/ipilimumab/nivolumabVarious toxicities: 2 case reports
    Reactions Weekly, 2021, 1854 (1) : 71 - 71
  • [4] Axicabtagene-ciloleucel/brexucabtagene-autoleucel/tisagenlecleucelMultiple toxicities: 12 case reports
    Reactions Weekly, 2022, 1932 (1) : 115 - 115
  • [5] Axicabtagene-ciloleucel/tisagenlecleucelCytokine release syndrome
    Reactions Weekly, 2024, 1989 (1) : 39 - 39
  • [6] Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
    Ahmed, Nausheen
    Wesson, William
    Lut, Forat
    Porter, David L.
    Bachanova, Veronika
    Nastoupil, Loretta J.
    Perales, Miguel-Angel
    Maziarz, Richard T.
    Brower, Jamie
    Shah, Gunjan L.
    Chen, Andy I.
    Oluwole, Olalekan O.
    Schuster, Stephen J.
    Bishop, Michael R.
    McGuirk, Joseph P.
    Riedell, Peter A.
    BLOOD ADVANCES, 2024, 8 (20) : 5346 - 5354
  • [7] Axicabtagene-ciloleucel/lisocabtagene-maraleucelCardiovascular death, new/worsening heart failure and new/worsening arrythmias
    Reactions Weekly, 2024, 2006 (1) : 108 - 108
  • [8] Axicabtagene-ciloleucel/cyclophosphamide/tisagenlecleucelHaematological toxicities and cytokine release syndrome: 2 case reports
    Reactions Weekly, 2021, 1866 (1) : 77 - 77
  • [9] Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan
    Tsutsue, Saaya
    Makita, Shinichi
    Asou, Hiroya
    Matsuda, Hiroyuki
    Yamaura, Reiko
    Taylor, Todd D.
    FUTURE ONCOLOGY, 2024, 20 (19) : 1333 - 1349
  • [10] Axicabtagene-ciloleucel/nivolumabLack of efficacy: 7 case reports
    Reactions Weekly, 2023, 1974 (1) : 68 - 68
12345